What BeyondSpring Pharmaceuticals does

BeyondSpring Pharmaceuticals is a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, principally Plinabulin, a small-molecule GEF-H1 agonist that promotes dendritic cell maturation and T-cell priming. Through a unique and reversible binding to tubulin, Plinabulin is designed to restore tumor sensitivity to PD-1/PD-L1 checkpoint inhibitors while simultaneously reducing chemotherapy-induced neutropenia. The lead program targets EGFR wild-type non-squamous non-small cell lung cancer (NSCLC) patients who have progressed after immune checkpoint inhibitor therapy, an indication where over 60% of patients develop resistance and where nine late-stage trials have failed to improve overall survival over docetaxel. The DUBLIN-3 Phase 3 trial (n=559) demonstrated median OS of 15.8 vs 11.7 months (HR 0.55) and was published in The Lancet Respiratory Medicine in 2024; DUBLIN-4 (n=442) is being designed as the FDA-aligned confirmatory registrational study. BeyondSpring retains a minority equity stake (approximately 14.4% after the January 2025 partial sale) in SEED Therapeutics, a separately funded targeted protein degradation company co-founded with Eli Lilly in 2020 that is advancing the RITE3 molecular glue platform with its lead RBM39 degrader ST-01156 entering Phase 1.

BeyondSpring operates as a pre-revenue clinical-stage company with no current product sales, generating no revenue and reporting a Q1 2026 net loss of $2.4 million from continuing operations. The business model is oriented toward eventual commercialization of Plinabulin through standard pharmaceutical channels (wholesale distributors, specialty pharmacies, hospital purchasing) following regulatory approval, with go-to-market planned via direct engagement with oncologists, key opinion leaders, and academic medical centers. Current revenue-equivalents derive from monetizing a portion of the SEED Therapeutics equity stake ($35.4 million sold in January 2025). Clinical development is supported by investigator-initiated studies at top cancer centers (MD Anderson, Memorial Sloan Kettering, Peking Union Medical College Hospital, Wuhan Union Hospital, Shanghai Chest Hospital) and through strategic drug-supply partnerships, notably with Merck (pembrolizumab supply for Studies 303 and 302). The company holds composition-of-matter patent protection for Plinabulin through 2036 in 40+ jurisdictions, with Hatch-Waxman extension potentially extending exclusivity to 2041.

Name

BeyondSpring Pharmaceuticals

Legal name

BeyondSpring Inc.

Website

https://beyondspringpharma.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

BeyondSpring Pharmaceuticals is a clinical-stage biopharmaceutical company developing Plinabulin, a first-in-class GEF-H1 agonist immune modulator for NSCLC patients who progress on checkpoint inhibitors, plus a minority stake in SEED Therapeutics' targeted protein degradation platform.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Clinical-stage biopharmaceutical
• Oncology drug development
• Cancer immunotherapy
• Immune checkpoint resistance
• Targeted protein degradation

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Future Product Sales: BeyondSpring is a clinical-stage biopharmaceutical company with no current revenue. The company is developing Plinabulin for cancer treatment and expects to generate revenue through product sales following regulatory approval. The company also retains equity stake in SEED Therapeutics (~14-38% ownership) which may generate future value.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

BeyondSpring Pharmaceuticals is a clinical-stage biopharmaceutical company developing Plinabulin, a first-in-class GEF-H1 agonist that promotes dendritic cell maturation for cancer treatment, with lead indications in non-small cell lung cancer (NSCLC) patients who have progressed after PD-1/PD-L1 checkpoint inhibitor therapy. The company also operates SEED Therapeutics, a subsidiary developing targeted protein degradation therapeutics using the proprietary RITE3 molecular glue platform, with lead candidate ST-01156 (RBM39 degrader) entering Phase 1 clinical development.

Product overview

BeyondSpring Pharmaceuticals is a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies. The company's lead product is Plinabulin, a GEF-H1 agonist and first-in-class dendritic cell maturation agent that has been studied in over 700 cancer patients across multiple Phase 1-3 clinical trials. Plinabulin is in late-stage development for NSCLC and other cancer indications, with positive results from the DUBLIN-3 Phase 3 trial published in The Lancet Respiratory Medicine. The company is advancing DUBLIN-4, a confirmatory Phase 3 registrational trial. The portfolio also includes SEED Therapeutics, a subsidiary developing targeted protein degradation therapeutics using the proprietary RITE3 molecular glue platform, with ST-01156 (RBM39 degrader) entering Phase 1 clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

• Plinabulin First-in-class, small-molecule immune modulator (GEF-H1 agonist) with differentiated mechanism for cancer treatment. Promotes dendritic cell maturation and robust T-cell priming, driving anti-tumor immune response. Studied in over 700 cancer patients across multiple Phase 1-3 clinical trials. Indicated for NSCLC patients who have progressed after PD-1/PD-L1 checkpoint inhibitor therapy.

Quantifiable outcome

• Median OS improvement: 15.8 vs 11.7 months (HR=0.55) in non-squamous EGFR WT NSCLC post anti-PD-(L)1
• +5 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered core.

• SEED Therapeutics Inc.coreStrategic or Co-development Partner · 28 January 2025SEED Therapeutics is a clinical-stage biotechnology company co-founded by BeyondSpring focused on targeted protein degradation. BeyondSpring retains approximately 14-38% equity stake following Series A-3 financing. SEED advances its RITE3 platform with lead program ST-01156 (RBM39 degrader) in Phase 1 clinical development.
• Wuhan Union HospitalcoreStrategic or Co-development Partner · 25 March 2024Phase 2 investigator-initiated study (NCT05745350) at Wuhan Union Hospital evaluating pembrolizumab, Plinabulin plus etoposide/platinum as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC), with Dr. Xiaorong Dong as principal investigator.
• Merck (MSD) - Investigator Studies ProgramcoreStrategic or Co-development Partner · 1 January 2023Merck provides funding and study drug (pembrolizumab/Keytruda) for investigator-initiated studies including Study 303 in NSCLC (NCT05599789) and Study 302 in SCLC (NCT05745350). Studies evaluate Plinabulin's ability to resensitize tumors to PD-1 checkpoint inhibitors through dendritic cell maturation.
• Eli Lilly and CompanycoreStrategic or Co-development Partner · 1 January 2020BeyondSpring co-founded SEED Therapeutics with Eli Lilly in 2020. Lilly is a cornerstone investor and collaborator in targeted protein degradation research. SEED's Series A-3 financing was led by Eisai with continued involvement from Lilly. Collaboration focuses on developing molecular glue degraders using SEED's RITE3 platform for diseases driven by undruggable proteins.
• Peking Union Medical College HospitalcoreStrategic or Co-development PartnerPhase 2 investigator-initiated Study 303 conducted at Peking Union Medical College Hospital in Beijing, China, evaluating Plinabulin plus docetaxel and pembrolizumab in 47 metastatic NSCLC patients who progressed on prior PD-1/L1 inhibitors.
• MD Anderson Cancer CentercoreStrategic or Co-development PartnerPhase 1 investigator-initiated study (NCT04902040) at MD Anderson demonstrating Plinabulin's ability to promote DC maturation and M1 macrophage polarization via GEF-H1-dependent mechanism in patients with 8 cancer types who failed prior PD-1/L1 inhibitors.
• Memorial Sloan Kettering Cancer CentercoreStrategic or Co-development PartnerPhase 1 investigator-initiated study collaboration in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation (AHCT), evaluating Plinabulin's ability to reduce infectious neutropenic fever and transfusion requirements.
• Shanghai Chest HospitalcoreStrategic or Co-development PartnerCollaboration with Shanghai Chest Hospital for ADC combination preclinical and clinical development, demonstrating China's ADC research ecosystem value in advancing Plinabulin's global development.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Arcus Biosciences: Clinical-stage immuno-oncology company developing combinations with checkpoint inhibitors (including adenosine and TIGIT pathways). Most directly comparable to BeyondSpring for its I/O-combination development strategy in NSCLC and other tumor types.
• Compugen: Clinical-stage immuno-oncology company focused on novel drug targets that combine with PD-1 inhibitors to overcome resistance. Comparable therapeutic thesis to Plinabulin's dendritic cell maturation approach for checkpoint-resistant tumors.
• Erasca: Clinical-stage precision oncology company developing therapies targeting the RAS/MAPK pathway with combination strategies. Similar clinical-stage profile and oncology development focus; also notable as BeyondSpring board member Jen Majeti previously served as Erasca's Head of Global Collaborations.
• Cogent Biosciences: Clinical-stage precision oncology company developing small-molecule kinase inhibitors for genomically defined cancers. Similar small-molecule clinical-stage profile with comparable capitalization and oncology focus.
• Spectrum Pharmaceuticals: Commercial and clinical-stage oncology company with a portfolio of hematology and oncology drugs including lung cancer products. Comparable oncology commercial-readiness profile though broader portfolio.
• Black Diamond Therapeutics: Clinical-stage precision oncology company developing small-molecule therapies against allosteric oncogenic mutations. Similar clinical-stage profile and small-molecule oncology development approach.
• Checkpoint Therapeutics: Clinical-stage immuno-oncology company developing anti-PD-L1 antibodies and targeted small molecules for lung cancer and other tumors. Direct overlap in checkpoint inhibitor + combination strategy for NSCLC.

Emerging players

• Mirati Therapeutics: Pre-acquisition by Bristol-Myers Squibb, Mirati was a clinical-stage oncology company focused on targeted oncology (KRAS, PRMT5) for NSCLC. Direct peer in lung cancer drug development though now part of BMS.
• Turning Point Therapeutics: Pre-acquisition by BMS, Turning Point was a clinical-stage precision oncology company developing next-gen kinase inhibitors for NSCLC. Comparable lung cancer drug development focus though now under BMS ownership.

Broad incumbents

• Blueprint Medicines: Commercial-stage precision therapy company developing kinase-targeted small molecules for oncology and rare diseases. Comparable small-molecule oncology drug developer with broader portfolio than BeyondSpring's single-asset focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/beyondspring-pharmaceuticals
• Xx.com/BeyondSpringInc

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries2 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BeyondSpring Pharmaceuticals